Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Lancet. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12.

Authors

Robert H Shaw¹, Arabella Stuart¹, Melanie Greenland¹, Xinxue Liu¹, Jonathan S Nguyen Van-Tam², Matthew D Snape³; Com-COV Study Group

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK.
² Division of Epidemiology and Public Health, School of Clinical Sciences, University of Nottingham, Nottingham, UK.
³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford OX3 9DU, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: matthew.snape@paediatrics.ox.ac.uk.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

BNT162 Vaccine
COVID-19 / epidemiology
COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / adverse effects*
COVID-19 Vaccines / immunology*
ChAdOx1 nCoV-19
Cross Protection / immunology
Humans
Immunity, Heterologous
Immunization, Secondary / adverse effects
Immunization, Secondary / methods*
Immunogenicity, Vaccine
Mass Vaccination / adverse effects
Mass Vaccination / methods*
SARS-CoV-2 / immunology

Substances

COVID-19 Vaccines
ChAdOx1 nCoV-19
BNT162 Vaccine